[1]Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management[J]. Cardiovasc Diagn Ther, 2017, 7:S276-S284. [2]Budnik I, Brill A. Immune factors in deep vein thrombosis initiation[J]. Trends Immunol, 2018, 39:610-623. [3]Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J]. Nature, 1998, 391:591-608. [4]Mirlekar B, Pylayeva-gupta Y. IL-12 family cytokines in cancer and immunotherapy[J]. cancers basel, 2021, 13:167-175. [5]李晓强, 张福先, 王深明. 深静脉血栓形成的诊断和治疗指南(第三版)[J]. 中华普通外科杂志, 2017, 32:250-257. [6]Kruger-genge A, Blocki A, Franke RP, et al. Vascular endothelial cell biology: an update[J]. Int J Mol Sci, 2019, 20:4411-4423. [7]Kawecki C, Lenting PJ, Denis CV. Von Willebrand factor and inflammation[J]. J Thromb Haemost, 2017,15:1285-1294. [8]Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis[J]. Blood, 2010, 116:4317-4327. [9]杜果城, 赵纪春, 张茂春, 等. 可溶性细胞表面分化抗原40配体在下肢深静脉血栓形成患者外周血中的表达[J]. 中国普外基础与临床杂志, 2018, 25:1454-1458. [10]Jin R, Xiao AY, Song Z, et al. Platelet CD40 mediates leukocyte recruitment and nNeointima formation after arterial denudation injury in atherosclerosis-prone mice[J]. Am J Pathol, 2018, 188:252-263. [11]Hou C, Wu Q, Ouyang C, et al. Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines[J]. Int J Mol Med, 2016, 38: 713-720. [12]Li X, Shao Y, Sha X, et al. IL-35 (Interleukin-35) suppresses endothelial cell activation by inhibiting mitochondrial reactive oxygen species-mediated site-specific acetylation of H3K14 (Histone 3 Lysine 14)[J]. Arterioscler Thromb Vasc Biol, 2018, 38:599-609. . [13]Ercan G, Yigitturk G, Erbas O. Therapeutic effect of adenosine on experimentally induced acute ulcerative colitis model in rats[J]. Acta Cir Bras, 2020, 34:e201901204. doi: 10.1590/s0102-865020190120000004. [14]Pan W, Xu X, Wang Y, et al. Interleukin-35 reduces inflammation in acute lung injury through inhibiting TLR4/NF-κB signaling pathways[J]. Exp Ther Med, 2020, 19:1695-1700. [15]Li X, Fang P, Sun Y, et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidyl-choline-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signa-ture in endothelial cells[J]. Redox Biol, 2020, 28:101373. doi: 10.1016/j.redox.2019.101373. |